Renata Pasqualini

USPTO Granted Patents = 41 (Patent Applications = 11)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 2.7

ph-index = 14

Forward Citations = 686(Granted Patents)

Location History:

Solana Beach, CA (US) (1997 - 2008)
Houston, TX (US) (2006 - 2020)
Los Ranchos de Albuquerque, NM (US) (2021)

Company Filing History:

20 out of 5,444

University of Texas System

patents

15 out of 94

The Burnham Institute

patents

4 out of 142

La Jolla Cancer Research Foundation

patents

4. 4 out of 512

Sloan-kettering Institute for Cancer Research

patents

5. 3 out of 630

William Marsh Rice University

where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12121525 - Methods for treating GI syndrome and graft versus host disease (2024-10-22),

2. 11207329 - Methods for treating GI syndrome and graft versus host disease (2021-12-28),

3. 10844365 - Systems and methods for magnetic guidance and patterning of materials (2020-11-24),

4. 9909116 - Systems and methods for magnetic guidance and patterning of materials (2018-03-06),

5. 9827327 - Methods and compositions related to adenoassociated virus-phage particles (2017-11-28),

6. 9592238 - Anti-ceramide monoclonal antibody 2A2 (2017-03-14),

7. 8846859 - Compositions and methods of use of targeting peptides against placenta and adipose tissues (2014-09-30),

8. 8815231 - Systems and methods for magnetic guidance and patterning of materials (2014-08-26),

9. 8710017 - Human and mouse targeting peptides identified by phage display (2014-04-29),

10. 8562993 - Methods for treating GI syndrome and graft versus host disease (2013-10-22),

11. 8507445 - Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer (2013-08-13),

12. 8470528 - Methods and compositions related to adenoassociated virus-phage particles (2013-06-25),

13. 8450278 - MUC18 targeting peptides (2013-05-28),

14. 8252764 - Compositions and methods of use of targeting peptides against placenta and adipose tissues (2012-08-28),

15. 8067377 - Peptide compositions for targeting adipose tissue (2011-11-29),

Title: Renata Pasqualini: Pioneering Inventor in Biomedical Treatments

Introduction: Renata Pasqualini, a brilliant inventor hailing from Houston, TX, is a leading figure in the field of biomedical research. With an impressive portfolio of 41 patents to her name, Pasqualini's groundbreaking work has revolutionized the treatment of various diseases.

Latest Patents: Among her most recent patents are innovative methods for treating GI syndrome and graft versus host disease. Through the use of anti-ceramide antibodies, Pasqualini has developed therapies that target diseases mediated by cytolytic T lymphocyte-induced killing and damage to endothelial microvasculature.

Career Highlights: Renata Pasqualini has made significant contributions during her tenure at esteemed institutions such as the University of Texas System and The Burnham Institute (now known as Sanford Burnham Prebys Medical Discovery Institute). Her dedication to advancing medical science has led to cutting-edge treatments that have the potential to transform healthcare outcomes.

Collaborations: Throughout her career, Pasqualini has collaborated with top researchers and experts in the field, including Wadih Arap and Erkki I. Ruoslahti. These partnerships have resulted in synergistic efforts that have propelled the development of novel therapeutic approaches.

Conclusion: Renata Pasqualini's unwavering commitment to innovation and her relentless pursuit of scientific excellence have solidified her reputation as a trailblazer in the field of biomedical research. Her patents reflect a deep understanding of complex diseases and a passion for improving patient outcomes. As she continues to push the boundaries of medical science, the impact of her pioneering work is poised to shape the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.